Sanofi ADR
USUSDSanofi ADR (VI:SANO) — Biotechnology: Pharmaceutical Preparations. Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 6. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- sanofi.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hauptsitz
- PARIS, France
- CEO
- Paul Hudson
- Mitarbeiter
- 106 566
- Gegründet
- 2004
- Börsennotiert seit
- 04.10.2017 (VI:SANO)
- Ausstehende Aktien
- 1.22 Mrd. Stand 2025-12-31
- Streubesitz
- 2.16 Mrd.
- Marktkapitalisierung
- 98.67 Mrd. USD
- Insider
- 0%
- Institutionelle Anleger
- 8.02%
- Branche (SIC)
- Pharmaceutical Preparations
- Rechtsform
- QVPB
- ISIN
- FR0000120578
- LEI
- 549300E9PC51EN656011
- Ausschüttungsquote
- 0%
- FCF
- 10.8 Mrd. EUR
- Schulden
- 18.7 Mrd. EUR1.0 J. FCF
- Dividendenserie
- 23 J.
- Gewinn, FCF und gezahlte Dividenden — für die 12 Monate bis 31.12.2025 (letzter Bericht des Unternehmens).
Beschreibung
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Börsen und Ticker
| Börse | Ticker | Währung | Preis | Typ |
|---|---|---|---|---|
| US USA Stocks | SNYNF OTC | USD | 79.9382 +2.14% | Stammaktie |
| LSE London Stock Exchange | 0O59 IOB | EUR | 71.63 +0.72% | Stammaktie |
| MI Borsa Italiana (Milan) | 1SAN zusätzlich | EUR | 71.64 +0.90% | Stammaktie |
| PA Euronext Paris | SAN primär | EUR | 71.52 +0.83% | Stammaktie |
| VI Vienna Stock Exchange | SANO zusätzlich | EUR | 71.3 +1.03% | Stammaktie |
| XETRA Xetra | SNW zusätzlich | EUR | 71.78 -1.21% | Stammaktie |
Dividenden
Sanofi ADR (SANO) zahlt einmal jährlich Dividenden. In den letzten 12 Monaten wurde 4.12 EUR pro Aktie gezahlt (Zahlungen: 1). Das entspricht etwa 5.78% des aktuellen Aktienkurses. Basierend auf der Zahlungshistorie wird der nächste Ex-Dividenden-Tag um den 04.05.2027 erwartet. Ununterbrochene Dividendengeschichte: 23 Jahre.
| Ex-Tag | Auszahlung | Betrag | % | Typ | Ticker |
|---|---|---|---|---|---|
| 2026-05-05 | 2026-05-07 | 4.1200 EUR | 5.8/5.8 % | jährlich | VI:SANO |
| 2025-05-12 | 2025-05-14 | 3.9200 EUR | 5.5/5.5 % | jährlich | VI:SANO |
| 2024-05-13 | — | 3.7600 EUR | 5.3/10.3 % | jährlich | VI:SANO |
| 2023-05-30 | — | 3.5600 EUR | 5.0/5.0 % | jährlich | VI:SANO |
| 2022-05-06 | — | 3.3300 EUR | 4.7/4.7 % | jährlich | VI:SANO |
Neuigkeiten diese Woche
Noch keine Nachrichten von der Website des Unternehmens.
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| Dodge & Cox Inc. | 10.54% | 28.09 Mio. | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 7.84% | 20.9 Mio. | 2026-06-30 |
| Morgan Stanley | 4.02% | 10.7 Mio. | 2026-06-30 |
| Fisher Asset Management,… | 3.99% | 10.63 Mio. | 2026-06-30 |
| Bank of America Corporat… | 3% | 8.01 Mio. | 2026-06-30 |
| Invesco Ltd. | 2.55% | 6.8 Mio. | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.47% | 6.57 Mio. | 2026-06-30 |
| Mondrian Investment Part… | 2.07% | 5.52 Mio. | 2026-06-30 |
| Brandes Investment Partn… | 1.55% | 4.14 Mio. | 2026-06-30 |
| AIM Sector Funds (Invesc… | 1.51% | 4.03 Mio. | 2026-04-30 |
| Federated Hermes, Inc. | 1.44% | 3.85 Mio. | 2026-06-30 |
| Boston Partners | 1.44% | 3.84 Mio. | 2026-06-30 |
| VANGUARD STAR FUNDS-Vang… | 1.31% | 15.85 Mio. | 2026-07-31 |
| Putnam ETF Trust-Putnam… | 1.26% | 3.36 Mio. | 2026-05-31 |
| VANGUARD TAX-MANAGED FUN… | 0.87% | 10.53 Mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.67% | 8.11 Mio. | 2026-08-31 |
| Dodge & Cox Funds-Dodge… | 0.63% | 1.67 Mio. | 2026-06-30 |
| AMERICAN MUTUAL FUND | 0.59% | 1.58 Mio. | 2026-06-30 |
| American Century Capital… | 0.37% | 976 561 | 2026-06-30 |
| Bridge Builder Trust-Bri… | 0.36% | 967 100 | 2026-06-30 |
| Fidelity Concord Street… | 0.35% | 4.24 Mio. | 2026-07-31 |
| VanEck ETF Trust-VanEck… | 0.35% | 938 561 | 2026-08-31 |
| Dodge & Cox Funds-Dodge… | 0.33% | 4.04 Mio. | 2026-06-30 |
| iShares Trust-iShares MS… | 0.32% | 3.89 Mio. | 2026-08-31 |
| Capital World Growth & I… | 0.3% | 3.67 Mio. | 2026-06-30 |
| -Victory Pioneer Core Eq… | 0.3% | 799 487 | 2026-06-30 |
| Fidelity Covington Trust… | 0.3% | 797 184 | 2026-08-31 |
| NEW PERSPECTIVE FUND | 0.29% | 3.56 Mio. | 2026-06-30 |
| Federated Hermes Eqy. Fd… | 0.29% | 3.48 Mio. | 2026-07-31 |
| Bridge Builder Trust-Bri… | 0.29% | 3.44 Mio. | 2026-06-30 |
| Pacer Advisors, Inc. | 0.1% | 1.16 Mio. | 2026-06-30 |
| Generali Investments Cee… | 0% | 29 339 | 2026-06-30 |
| Paradigm Asset Managemen… | 0% | 19 200 | 2026-06-30 |
| Gamma Investing LLC | 0% | 58 | 2026-06-30 |
| L'Oréal | — | — | — |
